Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Development of a 3D MRI-System for Earth Field MRI and the Combination MRI-MPI

Das Ziel dieser Arbeit war die Entwicklung und die Anfertigung eines 3D Erdfeld-NMR Tomographen, um damit die benötigte Technik der MR eines MR-MPI-Tomographen am Lehrstuhl zu etablieren. Daraufhin wurden alle nötigen Komponenten für ein komplettes 3D Erdfeld-NMR-System entwickelt, gebaut und getestet. Mit diesem Wissen wurde in enger Zusammenarbeit mit der MPI-Arbeitsgruppe am Lehrstuhl ein multimodaler MR-MPI-Tomograph angefertigt und die prinzipielle Machbarkeit der technischen Kombination dieser zwei Modalitäten (MRT/MPI) in einer einzigen Apparatur gezeigt. Auf diesem Entwicklungsweg sind zusätzlich innovative Systemkomponenten entstanden, wie der Bau eines neuen Präpolarisationssystems, mit dem das Präpolarisationsfeld kontrolliert und optimiert abgeschaltet werden kann. Des Weiteren wurde ein neuartiges 3D Gradientensystem entwickelt, das parallel und senkrecht zum Erdmagnetfeld ausgerichtet werden kann, ohne die Bildgebungseigenschaften zu verlieren. Hierfür wurde ein 3D Standard-Gradientensystem mit nur einer weiteren Spule, auf insgesamt vier Gradientenspulen erweitert. Diese wurden entworfen, gefertigt und anhand von Magnetfeldkarten ausgemessen. Anschließend konnten diese Ergebnisse mit der hier präsentierten Theorie und den Simulationsergebnissen übereinstimmend verglichen werden. MPI (Magnetic Particle Imaging) ist eine neue Bildgebungstechnik mit der nur Kontrastmittel detektiert werden können. Das hat den Vorteil der direkten und eindeutigen Detektion von Kontrastmitteln, jedoch fehlt die Hintergrundinformation der Probe. Wissenschaftliche Arbeiten prognostizieren großes Potential, die Hintergrundinformationen der MRT mit den hochauflösenden Kontrastmittelinformationen mittels MPI zu kombinieren. Jedoch war es bis jetzt nicht möglich, diese beiden Techniken in einer einzigen Apparatur zu etablieren. Mit diesem Prototyp konnte erstmalig eine MR-MPI-Messung ohne Probentransfer durchgeführt und die empfindliche Lokalisation von Kontrastmittel mit der Überlagerung der notwendigen Hintergrundinformation der Probe gezeigt werden. Dies ist ein Meilenstein in der Entwicklung der Kombination von MRT und MPI und bringt die Vision eines zukünftigen, klinischen, multimodalen MR-MPI-Tomographen ein großes Stück näher.Developement of an 3D MRI System for Earth Field MRI and the Kombination with MP

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

International audienc

Long-term (180-Day) outcomes in critically Ill patients with COVID-19 in the REMAP-CAP randomized clinical trial

Importance The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. Objective To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. Design, Setting, and Participants Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022. Interventions Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401). Main Outcomes and Measures The main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83. Results Among 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR >0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies. Conclusions and Relevance Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months